Brean Murray Positive on Vivus (VVUS) after Approval
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 23 | New: 27
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 23 | New: 27
Join SI Premium – FREE
Brean Murray Carret & Co. reiterated their Buy rating and $30 price target on Vivus (NASDAQ: VVUS) following FDA approval of Qsymia withouth harsh or unexpected restrictions.
The firm notes Qsymia will be on the market in 4Q12, importantly ahead of Arena's (Nasdaq: ARNA) competing drug Belviq.
"We believe that the restrictions placed upon Qsymia use are on the favorably mild end of the spectrum."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $26.46 yesterday.
The firm notes Qsymia will be on the market in 4Q12, importantly ahead of Arena's (Nasdaq: ARNA) competing drug Belviq.
"We believe that the restrictions placed upon Qsymia use are on the favorably mild end of the spectrum."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $26.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Downgrades Regions Financial (RF) to Neutral on Potential Revenue Shortfall
- Deutsche Bank Resumes Nemetschek (NEM:GR) at Buy
- Barclays Upgrades Lincoln National (LNC) to Overweight
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
